Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10900755 | 0.76 | HCRTR2 (0.49) | CDC25BHCRTR2 | |
| SCHEMBL27833999 | 0.76 | CYP3A4 (0.41) | ALOX15HSD17B10PTGS1PTGS2 | |
| SCHEMBL1846189 | 0.74 | MAP3K14 (0.50) | — | |
| SCHEMBL29590701 | 0.73 | POLB (0.47) | POLBCDC25BPTGS1PTGS2AKR1B1 | |
| SCHEMBL22614278 | 0.73 | POLB (0.47) | POLBCDC25BPTGS1PTGS2AKR1B1 | |
| SCHEMBL29159681 | 0.73 | POLB (0.47) | POLBCDC25BPTGS1PTGS2AKR1B1 | |
| SCHEMBL22614669 | 0.73 | POLB (0.47) | POLBCDC25BPTGS1PTGS2AKR1B1 | |
| SCHEMBL22613932 | 0.73 | POLB (0.47) | POLBCDC25BPTGS1PTGS2AKR1B1 | |
| SCHEMBL11523396 | 0.73 | POLB (0.47) | POLBCDC25BPTGS1PTGS2AKR1B1 | |
| SCHEMBL29499473 | 0.73 | POLB (0.47) | POLBCDC25BPTGS1PTGS2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | claimed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | claimed |
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NR3C2, MRGPRX2, HRH2 | POLB 2635/4885ALOX15 436/4885HSD17B10 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.